Nutriband Stock Price, News & Analysis

Nutriband (NASDAQ:NTRB) filed a provisional patent application with the USPTO on October 8, 2025 to strengthen intellectual property covering its AVERSA™ transdermal abuse deterrent technology. The filing targets improved aversive formulations and coating application methods designed to enhance deterrence for patches containing opioids and stimulants.

The company notes AVERSA is already covered by issued patents in 46 countries and says conversion to a non‑provisional application and a subsequent patent grant could extend U.S. patent protection (statutory term starts from the non‑provisional filing date).

Nutriband (NASDAQ: NTRB / NTRBW) will present at the Noble Capital Markets Emerging Growth Virtual Equity Conference on October 8, 2025. Chairman Serguei Melnik will deliver a formal presentation including a fireside Q&A at 3:00 PM Eastern, with live questions from the virtual audience.

Registered, qualified investors may request scheduled 1x1 meetings with management by contacting Giorgia Pigato at Noble Capital Markets. The live webcast will be available via Channelchek and will be archived on the company website and Channelchek for 90 days. Registration for the live presentation is free for attendees.

Nutriband Inc. (NASDAQ:NTRB) has announced its participation in the upcoming MicroCap Rodeo Conference in New York City on September 25, 2025. Company Chairman Serguei Melnik will deliver a presentation at 10:00 AM, focusing on operational highlights, growth initiatives, and the company's AVERSA platform technology.

The presentation will be available via live webcast, and management will conduct one-on-one meetings with approved investors. Interested parties can register for the virtual presentation through the conference website at www.microcaprodeo.com.

Nutriband (NASDAQ:NTRB) reported strong Q2 2025 financial results, with revenue reaching $1,289,884, marking a 50.87% increase year-over-year. The company maintains a robust cash position of $6.9 million, with total assets of $10.17 million and stockholders' equity of $8.5 million.

The company is advancing its lead product, AVERSA Fentanyl, with a scheduled Type C meeting on September 18th. Notably, the NDA filing will require only a single phase 1 Human Abuse Potential study, without the need for Phase 2 or 3 trials. Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.

Nutriband (NASDAQ:NTRB) has announced the exercise of warrants at a strike price of $6.43, generating gross proceeds of $5,306,000. The company will utilize these funds primarily for completing the clinical development of AVERSA Fentanyl and submitting its New Drug Application (NDA) to the FDA for marketing approval.

AVERSA Fentanyl is positioned to potentially become the first opioid patch with abuse deterrent properties. According to the Health Advances Aversa Fentanyl market analysis report 2022, the product could achieve peak annual US sales between $80 million to $200 million.

Nutriband Inc. (NASDAQ: NTRB) has announced its participation in the upcoming Emerging Growth Conference on August 20, 2025. The company's Chairman, Serguei Melnik, will deliver a presentation at 09:40 AM Eastern time for 30 minutes.

The interactive online event will allow shareholders and investors to engage directly with management through a Q&A session. Questions can be submitted in advance to Questions@EmergingGrowth.com or during the live event. For those unable to attend live, an archived webcast will be available on EmergingGrowth.com and the Emerging Growth YouTube Channel.

Nutriband (NASDAQ:NTRB) announced that CEO Gareth Sheridan will temporarily step down for three months to pursue candidacy in the Irish Presidential election. Chairman and President Serguei Melnik will serve as interim CEO during September and October 2025.

The company recently received FDA meeting approval for AVERSA Fentanyl, their abuse-deterrent opioid patch. The product has projected peak annual US sales potential of $80-200 million and is protected by patents in 46 countries. The company remains on track for its planned NDA filing in 2026.

Nutriband (NASDAQ:NTRB) has secured a Type C Meeting with the FDA for its AVERSA™ FENTANYL, a pioneering abuse-deterrent fentanyl transdermal system. The virtual meeting, scheduled for September 18, 2025, will focus on Chemistry, Manufacturing, and Controls (CMC) plans from IND submission through 505(b)(2) NDA approval.

The company is collaborating with Kindeva to combine Nutriband's AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. The product aims to be the world's first abuse-deterrent opioid patch, with projected peak annual US sales of $80-200 million. The technology is protected by patents in 46 countries, including major markets worldwide.

Nutriband (NASDAQ:NTRB) has announced key dates for its upcoming 25% preferred stock dividend. Shareholders of record as of July 25th, 2025 will receive one preferred share for every four common shares held, with the distribution set for August 5th.

The preferred shares come with two key features: they will be convertible to common stock upon FDA approval of the company's AVERSA Fentanyl product, and if not converted, shareholders will be entitled to an annual cash dividend from company profits, as determined by the Board of Directors.